Creative Biolabs adds integrated PK/PD support to lipid delivery services

Creative Biolabs on Aug. 10 said it has expanded its lipid-based drug delivery development workflow with integrated PK/PD support for gene therapy, RNA therapeutics and other preclinical programs. The offering is designed to help researchers move from formulation design to biological evaluation with fewer gaps in development.

Why it matters: - Advanced therapies such as gene editing products and RNA medicines often depend on delivery systems that can carry the payload, stay stable and behave predictably in the body. - Creative Biolabs is positioning its lipid-based workflow as a way for researchers to connect formulation choices with biological outcomes earlier in preclinical development. - That connection can help teams make better decisions on delivery design before candidates move deeper into development.

What happened: - Creative Biolabs said on Aug. 10, 2026, that it is strengthening its liposome and lipid-based drug delivery development solutions with integrated PK/PD support. - The company said the workflow covers lipid carrier design, formulation optimization, physicochemical characterization, biological evaluation and PK/PD assessment. - The service is aimed at biotechnology and pharmaceutical researchers working on gene therapy, RNA therapeutics and other drug development programs.

The details: - The lipid-based development workflow includes multiple optimization stages. - Those stages include lipid composition evaluation, payload compatibility assessment, particle characterization, formulation stability analysis and biological performance evaluation. - Creative Biolabs says it supports development of systems for nucleic acids, proteins and small molecules. - Liposome-based gene delivery support includes design and evaluation of lipid carriers for nucleic acids used in gene therapy and gene editing applications. - The company says it helps researchers assess delivery efficiency and improve liposome-based system performance. - Lipid formulation development support includes: - Lipid composition optimization - Payload compatibility assessment - Encapsulation efficiency evaluation - Particle size characterization - Formulation stability analysis - Delivery performance assessment - The company says these optimization steps are intended to improve quality and consistency for preclinical research applications. - PK/PD analysis support is meant to help researchers evaluate how delivery systems behave in biological environments. - The company says the service links formulation design with biological performance data to support preclinical decisions. - Creative Biolabs included a public product page for more information: More information.

Between the lines: - The announcement reflects a broader industry shift toward delivery platforms that are assessed as complete systems rather than as isolated formulation components. - PK/PD support adds a layer of translational analysis that can matter when a therapy’s success depends on how the carrier influences exposure, distribution and response. - The emphasis on multiple payload types suggests Creative Biolabs wants to serve a wider range of early-stage programs, not just one therapeutic class.

What's next: - Researchers using Creative Biolabs' services can apply the workflow to refine lipid carriers before advancing candidates into later preclinical work. - The company says it plans to support global researchers advancing gene therapy, RNA therapeutics and drug development programs. - Future development outcomes will likely depend on how well these integrated services reduce formulation uncertainty and improve in vivo predictability.

The bottom line: - Creative Biolabs is bundling formulation development and PK/PD analysis into one lipid-delivery offering to help preclinical teams build more predictive therapeutic systems.